ArticleJournal of medical case reports2026
Bilateral atypical femoral fractures following unsupervised long-term alendronate use: a case report.
Article in Journal of medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWe report a case of bilateral atypical femoral fractures in a 70-year-old Asian (Iranian) woman following 15 years of unsupervised alendronate use for osteoporosis. Although bisphosphonates are widely used to reduce fracture risk, long-term therapy without periodic reassessment may result in serious complications such as atypical femoral fractures (AFFs). CASE PRESENTATION: A 70-year-old Asian (Iranian) woman presented with bilateral atypical femoral fractures following 15 years of unsupervised alendronate use for osteoporosis. This case is notable because the medication was obtained through a pharmacist family member without specialist monitoring or consideration of drug holidays. Additionally, the patient deliberately avoided calcium supplementation due to concerns about constipation and kidney stones, which may have further compromised bone health. Mild prodromal symptoms were initially misattributed to age-related conditions, and radiographic evaluation was delayed until complete fractures occurred.
conclusionUltimately, further clinical follow-up was not feasible due to the patient's relocation to another city and subsequent unavailability. This case illustrates the risks of unsupervised long-term bisphosphonate therapy and underscores the need for structured prescription monitoring, patient education on balanced supplementation, and early imaging of prodromal symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.